CA3069336A1 - Promoting hair growth and treatment of hair loss or excessive hair shedding - Google Patents

Promoting hair growth and treatment of hair loss or excessive hair shedding Download PDF

Info

Publication number
CA3069336A1
CA3069336A1 CA3069336A CA3069336A CA3069336A1 CA 3069336 A1 CA3069336 A1 CA 3069336A1 CA 3069336 A CA3069336 A CA 3069336A CA 3069336 A CA3069336 A CA 3069336A CA 3069336 A1 CA3069336 A1 CA 3069336A1
Authority
CA
Canada
Prior art keywords
minoxidil
hair
range
concentration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069336A
Other languages
English (en)
French (fr)
Inventor
Rodney Sinclair
Original Assignee
Samson Clinical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902722A external-priority patent/AU2017902722A0/en
Application filed by Samson Clinical Pty Ltd filed Critical Samson Clinical Pty Ltd
Publication of CA3069336A1 publication Critical patent/CA3069336A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CA3069336A 2017-07-12 2018-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding Pending CA3069336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902722A AU2017902722A0 (en) 2017-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding
AU2017902722 2017-07-12
PCT/AU2018/050719 WO2019010535A1 (en) 2017-07-12 2018-07-12 STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA

Publications (1)

Publication Number Publication Date
CA3069336A1 true CA3069336A1 (en) 2019-01-17

Family

ID=65001077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069336A Pending CA3069336A1 (en) 2017-07-12 2018-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding

Country Status (10)

Country Link
US (2) US20190269684A1 (cg-RX-API-DMAC7.html)
EP (1) EP3651769B1 (cg-RX-API-DMAC7.html)
JP (2) JP7191927B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240064747A (cg-RX-API-DMAC7.html)
CN (1) CN111065396A (cg-RX-API-DMAC7.html)
AU (2) AU2018250398B2 (cg-RX-API-DMAC7.html)
CA (1) CA3069336A1 (cg-RX-API-DMAC7.html)
ES (1) ES2909395T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202000124PA (cg-RX-API-DMAC7.html)
WO (1) WO2019010535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
GB2596942B (en) 2019-02-27 2023-05-10 Samson Clinical Pty Ltd Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding
WO2021178871A1 (en) 2020-03-05 2021-09-10 University Of Miami Cannabidiol nanodrug formulations and methods for use the same
CN112691187B (zh) * 2020-12-30 2021-12-21 深圳新发源植物科技发展有限公司 一种用于防止额前脱发的缓释膜及其制备方法
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
KR20250100660A (ko) 2022-10-25 2025-07-03 베라더믹스 인코포레이티드 변형 방출 미녹시딜의 조성물 및 사용 방법
EP4539816A4 (en) * 2023-09-01 2025-07-23 Follea Int COMPOSITIONS AND METHODS FOR AN ORALLY ADMINISTERED MINOXIDIL SUPPLEMENT FOR THE TREATMENT OF ALOPECIA
KR20260065905A (ko) * 2023-09-08 2026-05-11 수조우 킨터 제약회사(주) 안드로겐 수용체 억제제/길항제를 함유하는 약학 조성물, 방법 및 용도
GB2638418A (en) * 2024-02-21 2025-08-27 Novumgen Ltd An orodispersible tablet of spironolactone and its process of preparation
WO2026062695A1 (en) * 2024-09-17 2026-03-26 Shah Atul K Toothpaste for body disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
CN1838969A (zh) * 2004-10-07 2006-09-27 三仪股份有限公司 经皮和经粘膜制剂
JP2009091325A (ja) * 2007-10-11 2009-04-30 Rohto Pharmaceut Co Ltd 育毛剤
EP2344198B1 (en) * 2008-09-27 2020-11-04 Jina Pharmaceuticals Inc. Lipid based pharmaceutical preparations for topical application
EP2510930A1 (en) * 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
NZ732075A (en) * 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US9561224B1 (en) * 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia

Also Published As

Publication number Publication date
AU2018250398B2 (en) 2019-02-28
WO2019010535A1 (en) 2019-01-17
AU2019203438A1 (en) 2019-06-06
AU2018250398A1 (en) 2019-01-31
CN111065396A (zh) 2020-04-24
ES2909395T3 (es) 2022-05-06
KR20240064747A (ko) 2024-05-13
JP2023016964A (ja) 2023-02-02
SG11202000124PA (en) 2020-02-27
US20190269684A1 (en) 2019-09-05
EP3651769A1 (en) 2020-05-20
JP7191927B2 (ja) 2022-12-19
EP3651769B1 (en) 2022-01-05
US20250064807A1 (en) 2025-02-27
KR102663164B1 (ko) 2024-05-07
NZ760579A (en) 2024-09-27
EP3651769A4 (en) 2021-04-21
JP2020527146A (ja) 2020-09-03
BR112020000508A2 (pt) 2020-07-14
KR20200028403A (ko) 2020-03-16

Similar Documents

Publication Publication Date Title
US20250064807A1 (en) Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding
US6458384B2 (en) Pharmaceutical with predetermined activity profile
AU2017203009B2 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
US20080038355A1 (en) Bioadhesive dosage form of steroids
KR102158948B1 (ko) 약물 전달 시스템
EP3313408B1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
JP2022508317A (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
US20250381192A1 (en) Treatment of Autoimmune Disease
KR20130048227A (ko) 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트
CN115998740A (zh) 毛发过度脱落的检测和治疗
JP2005506987A (ja) 感覚的に許容される口内崩壊性組成物
US20170014340A1 (en) Orally Disintegrating Tablet of Nabilone Comprising Mannitol-Based Granules
AU2022200479A1 (en) Treatment of autoimmune disease
CA2505861A1 (en) Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
JP2000502346A (ja) 皮膚炎の処置方法
US20250017932A1 (en) Methods of Administering Elagolix
HK40018518B (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
HK40018518A (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
Kulkarni et al. A systematic review on oral drug delivery as a fast dissolving film to improve therapeutic effectiveness
BR112020000508B1 (pt) Composição orodispersível e uso de uma composição orodispersível
BR122025006573A2 (pt) Composição dispersível
EP3108889A1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
ES2725009T3 (es) Comprimidos con un alto contenido de principios activos útiles para el tratamiento de la pérdida de cabello o la estimulación de su crecimiento
OA18512A (en) Drospirenone-based contraceptive for a female patient affected with excess weight.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220901

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250402

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250715

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250715

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250825

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260210

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260306

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260501

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260615

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260616